178 related articles for article (PubMed ID: 12195090)
1. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients.
Dose J; Bleckmann C; Bachmann S; Bohuslavizki KH; Berger J; Jenicke L; Habermann CR; Jãnicke F
Nucl Med Commun; 2002 Sep; 23(9):857-64. PubMed ID: 12195090
[TBL] [Abstract][Full Text] [Related]
2. [Detection of metastases in breast cancer patients: comparison of FDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen].
Dose-Schwarz J; Mahner S; Schirrmacher S; Jenicke L; Müller V; Habermann CR; Brenner W
Nuklearmedizin; 2008; 47(3):97-103. PubMed ID: 18493688
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
Jung NY; Yoo IR; Kang BJ; Kim SH; Chae BJ; Seo YY
Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
[TBL] [Abstract][Full Text] [Related]
4. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
[TBL] [Abstract][Full Text] [Related]
5. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
6. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
7. Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.
Mahner S; Schirrmacher S; Brenner W; Jenicke L; Habermann CR; Avril N; Dose-Schwarz J
Ann Oncol; 2008 Jul; 19(7):1249-1254. PubMed ID: 18356138
[TBL] [Abstract][Full Text] [Related]
8. 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography in staging of locally advanced breast cancer.
van der Hoeven JJ; Krak NC; Hoekstra OS; Comans EF; Boom RP; van Geldere D; Meijer S; van der Wall E; Buter J; Pinedo HM; Teule GJ; Lammertsma AA
J Clin Oncol; 2004 Apr; 22(7):1253-9. PubMed ID: 15051773
[TBL] [Abstract][Full Text] [Related]
9. Detection of unknown primary tumours and distant metastases in patients with cervical metastases: value of FDG-PET versus conventional modalities.
Regelink G; Brouwer J; de Bree R; Pruim J; van der Laan BF; Vaalburg W; Hoekstra OS; Comans EF; Vissink A; Leemans CR; Roodenburg JL
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1024-30. PubMed ID: 12173016
[TBL] [Abstract][Full Text] [Related]
10. 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques.
Koolen BB; Vrancken Peeters MJ; Aukema TS; Vogel WV; Oldenburg HS; van der Hage JA; Hoefnagel CA; Stokkel MP; Loo CE; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
Breast Cancer Res Treat; 2012 Jan; 131(1):117-26. PubMed ID: 21935602
[TBL] [Abstract][Full Text] [Related]
11. Role of [18F]fluorodeoxyglucose positron emission tomography-computed tomography, sonography, and sonographically guided fine-needle aspiration biopsy in the diagnosis of axillary lymph nodes in patients with breast cancer: comparison of diagnostic performance.
Sohn YM; Hong IK; Han K
J Ultrasound Med; 2014 Jun; 33(6):1013-21. PubMed ID: 24866608
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
Kresnik E; Mikosch P; Gallowitsch HJ; Kogler D; Wiesser S; Heinisch M; Unterweger O; Raunik W; Kumnig G; Gomez I; Grünbacher G; Lind P
Eur J Nucl Med; 2001 Jul; 28(7):816-21. PubMed ID: 11504077
[TBL] [Abstract][Full Text] [Related]
13. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
[TBL] [Abstract][Full Text] [Related]
14. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
[TBL] [Abstract][Full Text] [Related]
16. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
17. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.
Brandt-Mainz K; Müller SP; Görges R; Saller B; Bockisch A
Eur J Nucl Med; 2000 May; 27(5):490-6. PubMed ID: 10853802
[TBL] [Abstract][Full Text] [Related]
18. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
20. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer comparison with computed tomography.
Meltzer CC; Luketich JD; Friedman D; Charron M; Strollo D; Meehan M; Urso GK; Dachille MA; Townsend DW
Clin Nucl Med; 2000 Nov; 25(11):882-7. PubMed ID: 11079584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]